Page 8 - Pneumococcal News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Pneumococcal. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Pneumococcal Today - Breaking & Trending Today

Pfizer Inc.: European Medicines Agency Approves Pfizer's 20-Valent Pneumococcal Conjugate Vaccine Against Invasive Pneumococcal Disease and Pneumonia in Adults

APEXXNAR [pneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)] is the first pneumococcal conjugate vaccine to help protect adults ages 18 years and older against 20 serotypes responsible ....

United States , Nanette Cocero , Drug Administration , Exchange Commission , Pfizer Inc , European Union , European Medicines Agency , Committee For Medicinal Products Human Use , Global President , Medicinal Products , Human Use , Marketing Authorization Application , Conjugate Vaccine , Biologics License Application , Breakthroughs That Change Patient , Pfizer News , Annual Report , Looking Information , Factors That May Affect Future , Conjugate Vaccination , Clin Microbiol , Deaths Attributable , Invasive Pneumococcal Disease , Different Vaccines , Years Study , Pneumococcal Vaccines ,

Pfizer's PREVNAR 20 Vaccine Receives FDA Approval for Adults Aged 18 and Above

Pfizer (PFE) has received approval from the U.S. Food and Drug Administration (FDA) for its Pneumococcal 20-valent Conjugate vaccine, PREVNAR 20, for preventing invasive pneumococcal disease and pneumonia in adults aged 18 and above. Following this approval, the U.S. Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices will be meeting in October to evaluate and update recommendations for the safe and appropriate use of the vaccine in adults. Kathrin U. Jansen ....

Food And Drug Administration , Revnar 13 Vaccine , Vaccine Research And Development , Neumonia In Adults , S Centers For Disease Control And Preventions Advisory Committee On Immunization Practices , Conjugate Vaccine , Senior Vice President ,

Vaccines Market Size to Reach USD 73.78 Billion in 2028;

Vaccines Market Size to Reach USD 73.78 Billion in 2028; Increasing government funding for vaccine production and growing emphasis on immunization are major factors expected to drive the market, Says Reports and Data
The major players in the global vaccines market are GlaxoSmithKline plc, Pfizer, Inc, Merck & Co., Inc. and Sanofi Pasteur, CSL Limited, Emergent BioSolutions, Inc., Johnson & Johnson, Serum Institute of India, AstraZeneca, Bavarian Nordic , Mitsubishi Tanabe Pharma Corporation, and Daiichi Sankyo Company, Limited.
June 02, 2021 13:43 ET
| Source:
Reports and Data
Reports and Data
New York, June 02, 2021 (GLOBE NEWSWIRE)
Market Size – USD 42 Billion
in 2020 Market Growth – 7.3% Market Trends – Expanding pharmaceutical industry and drive to vaccinate all ....

New York , United States , South Africa , Saudi Arabia , Sanofi Pasteur , Asia Pacific , Biotechnology Companies , Academic Research Institutes , Daiichi Sankyo Company , Mitsubishi Tanabe Pharma Corporation , Emergent Biosolutions Inc , Technology Outlook Revenue , Route Of Administration Outlook Revenue , Merck Co Inc , Pfizer Inc , Serum Institute Of India , Head Of Business Development , Market Trends , Global Vaccine Action Plan , World Health Assembly , Key Highlights , North America , Sankyo Company , Indication Outlook , Administration Outlook , Type Outlook ,

EMA Accepts Pfizer's MAA For 20-valent Pneumococcal Conjugate Vaccine Candidate For Adults

EMA Accepts Pfizer s MAA For 20-valent Pneumococcal Conjugate Vaccine Candidate For Adults
NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) said the European Medicines Agency (EMA) has accepted the Marketing Authorization Application (MAA) for its 20-valent pneumococcal conjugate vaccine candidate for the prevention of invasive disease and pneumonia caused by Streptococcus pneumoniae serotypes in adults 18 years of age and older.
The epidemiology of pneumococcal serotypes causing disease has been changing due to the success of pneumococcal conjugate vaccines targeting pediatric and adult populations. In many countries across Europe and around the world, more than half of all cases of invasive pneumococcal disease in older adults are due to the 20 serotypes covered in 20vPnC, including seven serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F) that are not included in any currently licensed pneumococcal conjugate vaccine, said Kathrin U. Jansen, Senior Vice President and Head of V ....

Kathrinu Jansen , Pfizer Inc , Head Of Vaccine Research , European Medicines Agency , Marketing Authorization Application , Senior Vice President , Vaccine Research , ஃபைசர் இன்க் , தலை ஆஃப் தடுப்பூசி ஆராய்ச்சி , சந்தைப்படுத்தல் அங்கீகாரம் விண்ணப்பம் , மூத்தவர் துணை ப்ரெஸிடெஂட் , தடுப்பூசி ஆராய்ச்சி ,

Merck: FDA Accepts For Priority Review BLA For Adult Invasive Pneumococcal Vaccine

KENILWORTH (NJ) (dpa-AFX) - Merck & Co Inc. (MRK) said Tuesday that the U.S. Food and Drug Administration accepted for priority review a Biologics License Application or BLA for V114 for the ....

Merck Co Inc , European Medicines Agency , Drug Administration , Biologics License Application , Prescription Drug User Fee Act , Breakthrough Therapy Designation , மெர்க் இணை இன்க் , உயிரியல் உரிமம் விண்ணப்பம் , ப்ரிஸ்க்ரிப்ஶந் மருந்து பயனர் கட்டணம் நாடகம் , திருப்புமுனை சிகிச்சை பதவி ,